This study looks at how well a new medicine called PF-08046054 works compared to the standard treatment, docetaxel, in adults with non-small cell lung cancer (NSCLC). The goal is to learn if PF-08046054 can help those whose cancer has progressed after other treatments. Participants will be assigned by chance to receive either PF-08046054 or docetaxel. The study may last up to 5 years if the treatment is helping.
The trial's ID number is NCT07144280. This is a Phase 3 trial, which means it is looking at how well the treatment works and how safe it is. The trial is FDA-regulated and aims to include about 680 participants.
Who can join
This trial is open to adults aged 18 and older with non-small cell lung cancer that cannot be removed by surgery. Both men and women can join. Participants must have cancer that has spread or cannot be treated with radiation. The study team will make sure anyone interested meets the eligibility requirements.
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly assigned to one of two groups. One group will receive PF-08046054 through an IV infusion twice every 21 days. The other group will receive docetaxel through an IV infusion once every 21 days. Regular visits will help the team monitor how well each person is doing with the treatment.
Where
This trial is enrolling at 133 locations. Recruiting sites are listed first.
Chief of Thoracic Surgery and Director of the Lung Cancer Program at West Virginia University Cancer Institute. Treats lung cancer and esophageal cancer.
Treats pancreatic cancer, lung cancer and colorectal cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Led the National Lung Screening Trial. Treats lung cancer. Other doctors who help with cancer care, like gastroenterologists, dermatologists, and endocrinologists. Recognized at state, national or international level.